Canaccord Genuity Keeps Their Buy Rating on Wayland Group Corp (WAYL)

In a latest note to investors, a research analyst has provided a rating update for the Healthcare company, Wayland Group Corp (WAYL). Analyst Derek Dley from Canaccord Genuity remains bullish on the stock and has a C$3 price target.

According to, Dley is ranked #858 out of 5142 analysts.

Read also: Does Amarin’s (AMRN) Impending FDA Decision Matter?

Currently, the analyst consensus on Wayland Group Corp is a Moderate Buy with an average price target of C$3.

Based on Wayland Group Corp’s latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of C$12.15 million. In comparison, last year the company had a GAAP net loss of C$5.38 million.

Maricann Group, Inc. is a medical cannabis company, which engages in the distribution of marijuana for medical purposes. It offers a variety of oil and flower products. It operates a medical cannabis cultivation, extraction, and formulation business under federal license from the Government of Canada.